Eli Lilly and Company stock price, LLY

Eli Lilly and Company stock chart:



Eli Lilly and Company close price: 80.19

Stock price forecast:

UP TO +0.47%
Target: 80.57

Total forecasts: 52
Reached: 19 (36.54%)

Total Win: 20.36 (24.70%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
No results found.

Showing 1-10 of 528 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-05-2980.1980.580000-00-00
2017-05-2880.1980.670000-00-00
2017-05-2780.1980.620000-00-00
2017-05-2680.1980.620000-00-00
2017-05-2580.1980.50000-00-00
2017-05-2480.1980.380000-00-00
2017-05-2380.1979.590000-00-00
2017-05-2280.1979.260000-00-00
2017-05-2180.1979.320000-00-00
2017-05-2080.1979.320000-00-00

Eli Lilly and Company latest news:


  • 05/12/2017 05:35:55

    UPDATE: Eli Lilly reports positive results in trial of migraine treatment

    Shares of Eli Lilly and Co. jumped 1.6% in premarket trade Friday, after the company said a late-stage study of a migraine treatment met its primary goals. The trial of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint. "The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this serious disease," Christi Shaw, president of Lilly Bio-Medicines, said in a statement. The company is now planning to submit a biologics license application to the U.S. Food and Drug Administration in the second half. More than 38 million Americans suffer from migraine, which affects three times more women than men. Lilly shares have gained 9% in 2017 through Thursday, while the S&P 500 has gained 7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/12/2017 05:00:34

    Eli Lilly reports positive results in trial of migraine treatment

    Eli Lilly and Co. said Friday a late-stage study of a migraine treatment met its primary goals. The trial of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint. "The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this serious disease," Christi Shaw, president of Lilly Bio-Medicines, said in a statement. The company is now planning to submit a biologics license application to the U.S. Food and Drug Administration in the second half. More than 38 million Americans suffer from migraine, which affects three times more women than men. Lilly shares were indicating higher in premarket trade, and are up 9% in 2017, while the S&P 500 has gained 7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/01/2017 10:15:34

    Eli Lilly says it has received civil investigative demands about insulin pricing from two state attorney generals

    Eli Lilly & Co. has received civil investigative demands related to its insulin prices from the attorney generals in Washington State and New Mexico, according to a 10-Q financial filing. The Washington State AG's office demand has to do with insulin prices as well as "our relationships with pharmacy benefit managers," industry middlemen that negotiate drug prices, while the demand from the New Mexico AG's office asked about insulin pricing, according to the 10-Q. Eli Lilly is cooperating with both investigations, it said. Insulin prices have skyrocketed over the last several years, making it challenging for diabetics to afford the medication. Eli Lilly, a major insulin manufacturer, has benefited from the industry-wide trend. Eli Lilly shares slumped 0.1% at $81.98 in midday trade on Monday. Shares have risen 5.6% over the last three months, compared with a 4.9% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/27/2017 07:05:23

    Top Analyst Upgrades and Downgrades: Amex, Cisco, Eli Lilly, First Solar, McDonald’s, Microsoft, US Steel and More


  • 04/25/2017 10:33:17

    UPDATE 3-Lilly gives no time frame on arthritis drug delay; shares fall

    April 25 (Reuters) - Eli Lilly and Co on Tuesday provided no new information on how long U.S. regulators might delay approval of its closely watched rheumatoid arthritis drug after its surprise rejection by the Food and Drug Administration this month.

  • 04/25/2017 06:52:02

    Eli Lilly swings to loss though sales rise, cuts outlook

    Eli Lilly & Co. on Tuesday said it swung to a quarterly net loss, but adjusted earnings and revenue exceeded expectations. The drug maker swung to a first-quarter loss of $110.8 million, or 10 cents a share, stemming from Lilly's purchase of CoLucid Pharmaceuticals Inc., which closed in March. On an adjusted basis, per-share earnings were 98 cents a share, above the 96 cents a share expected in a FactSet survey of analysts. Revenue for the period rose to $5.23 billion from $4.87 billion. Wall Street anticipated sales of $5.215 billion. Lilly lowered its 2017 net earnings forecast to $2.60 to $2.70 a share, citing severance costs. It previously forecast earnings of $2.69 to $2.79 a share. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/17/2017 08:20:54

    FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte


  • 04/17/2017 05:38:43

    Eli Lilly and Incyte stock drops after FDA fails to approve rheumatoid arthritis drug

    Eli Lilly & Co. shares dropped 5.5% and Incyte Corp. shares dropped 12.7% in premarket trade Monday after the companies said that the Food and Drug Administration failed to approve their drug for moderate-to-severe rheumatoid arthritis. Eli Lilly reaffirmed its financial guidance for this year, and Incyte said it is evaluating the news' impact and would provide any update on its first-quarter earnings call. (Incyte's earnings are scheduled for May 4.) The FDA told the two companies that more clinical data are required to figure out dosage information and safety concerns across groups of patients. New clinical trials could greatly extend the timeline for drug approval. But Eli Lilly and Incyte said they "disagree with the agency's conclusions" and said they would continue to work with the FDA to find a path to approval. Incyte shares have surged 23.9% over the last three months, and Eli Lilly shares have surged 11.8%, compared with a 2.7% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Ellie MaeELLI | Ellington Financial LLCEFC | Ellington Residential Mortgage REITEARN | Embotelladora Andina S.A.AKO.A | Embotelladora Andina S.A.AKO.B | Embraer-Empresa Brasileira de AeronauticaERJ | EMC CorporationEMC | EMCOR GroupEME | Emerge Energy Services LPEMES | Emergent BiosolutionsEBS |